11:51 , Apr 18, 2019 |  BC Innovations  |  Emerging Company Profile

Phenomic AI: phenotypic screening for antibody discovery

Phenomic is developing a deep-learning platform that uses high-content imaging and neural networks to analyze phenotypic changes in disease models to discover therapeutic antibodies more rapidly than conventional methods. Current image analysis tools work well...
22:45 , Apr 12, 2019 |  BioCentury  |  Emerging Company Profile

Bright Angel: New hope against fungal resistance

Bright Angel is tackling antifungal resistance at its root with inhibitors of Hsp90 and other stress response factors, unlike competitors that are developing compounds against known or new pathways where resistance can still emerge. Resistance...
01:50 , Mar 8, 2019 |  BC Innovations  |  Emerging Company Profile

Janpix picks STAT inhibitors for blood cancers

Janpix is developing STAT3 and STAT5 inhibitors that could treat hematologic malignancies with greater durability and lower risk of side effects than other inhibitors of the JAK-STAT pathway. Janpix Inc. in-licensed its family of small...
21:04 , Feb 7, 2019 |  BC Innovations  |  Emerging Company Profile

Tara’s beating heart

Tara Biosystems Inc. is using its heart-on-a-chip platform to uncover cardiac toxicity signals in drug candidates for biopharmas as it ventures into new drug discovery. Tara’s core technology is a 3-D cardiomyocyte culture system that...
19:38 , Jan 16, 2019 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Patient sample and mouse studies suggest adoptive transfer, or promoting the survival, of IgA-positive plasmablasts and plasma cells could help treat MS. In fecal samples from relapsing-remitting MS (RRMS) patients, counts...
19:37 , Jan 16, 2019 |  BC Innovations  |  Translation in Brief

Promoting gut plasmablasts for MS

Researchers from the University of Toronto and colleagues have linked the gut-brain axis to multiple sclerosis by showing gut plasmablasts and plasma cells suppress CNS inflammation during active MS, and suggested therapies that promote the...
22:04 , Jan 8, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Mouse studies suggest PPARα agonists could enhance the efficacy of adoptive T cell therapies for melanoma. In a mouse model of melanoma, adoptive transfer of CD8 + T cells pretreated with a tool...
23:40 , Dec 14, 2018 |  BioCentury  |  Emerging Company Profile

ExCellThera’s safer allogeneic transplants

ExCellThera Inc. is expanding cord blood into allogeneic stem cell transplants for cancer that have lower treatment-related mortality rates and GvHD incidence than competing technologies. Hematopoietic stem cell transplants (HSCTs) of unexpanded cord blood have...
04:21 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
20:33 , Oct 31, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Animal models E-cadherin (CDH1)-deficient mice with activated PI3KCA could be used to screen therapies for invasive lobular breast carcinoma. Mice engineered to express mutant, inactive CHD1 and constitutively active PI3KCA recapitulated multiple features of...